1Mano MS, Awada A, Di Leo A,et al. Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. Gynecol Oncol, 2004,92:887-895.
2Baselga J. Clinical trials of single-agent trastuzumab (Herceptin). Semin Oncol, 2000,27:20-26.
3Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.Cancer Res,1998,58:2825-2831.
4Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol,1999, 26:51-59.
5Fornier M, Esteva FJ, Seidman AD. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer.Semin Oncol, 2000,27:38-45.
6Pegram M, Hsu S, Lewis G,et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.Oncogene,1999,18:2241-2251.
8Wiechen K, Karaaslan S, Turzynski A, et al. Suppression of the c-erbB-2 gene product decreases transformation abilities but not the proliferation and secretion of proteases of SK-OV-3 ovarian cancer cells.Br J Cancer,1999,81:790-795.
2Baselga J, Tripathy D, Mendelsohn J, et al, Phase II study of weekly intravenous recombiTmnt humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. JClin Oncol, 1996, 14: 737-744.
3Vogel CL, Cobleigh MA, Tripalhy D, et al. First-line herceptin monolherapy in metastatic breast cancer. Oncology 2001,61 ( Suppl2).37-42.
4Fomier M, Esteva FJ, Seidman AD. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Semin-Oncol,2000, 27: 38-45.
5Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res, 1998, 58: 2825-2831.
1Kurebayashi J. Biological and clinical significance of HER -2 overexpression in breast cancer [J]. Breast Cancer, 2001,8 ( 1 ) :45 - 51.
2Hung MC, Lau YK. Basic science of HER - 2/neu : a review [J]. Semin Oncol, 1999,26 : 51 - 9.
3Cook GB , Neaman IE , Goldblatt JL , et al. Clinical utility of serum HER2/ neu testing on the Bayer Immunoautomated system in breast cancer [J]. Anticancer Res , 2001 ,21: 1465 - 1470.
4Hudelist G, Kostler WJ, Attems J, et al. Her -2/neu -triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab - based treatment[J]. Br J Cancer,2003,89(6) :983 -91.
5Schulze G. HER - 2/neu gene product in serum - an oncoprotein in the diagnosis and therapy of breast carcinoma [ J ]. Anticancer Res, 2003,23(2) :1007 - 10.
6Meenakshi A, Kumar RS, Kumar NS. ELISA for quantitation of serum C - erbB - 2 oncoprotein in breast cancer patients[J]. J Immunoassay Immunochem ,2002,23 ( 3 ) :293 - 305.
7Hayes DF,Yamauchi H, Broadwater G, et al. Circulating HER -2/ erbB - 2/c - neu ( HER - 2 ) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662 [J]. Clin Cancer Res,2001,7 (9) :2703 - 11.
8Sugano K, Ushiama M, Fukutomi T, Tsuda H, Kitoh T, Ohkura H. Combined measurement of the c - erbB - 2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse[J]. Int J Cancer,2000,89 (4) :329 -36.
9Colomer R, Llombart - Cussac A, Lluch A, et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain [ J ]. Ann Oncol, 2004,15(2) :201 -6.
10Felip E, Del Campo JM, Rubio D, et al. Overexpression of c -erbB -2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy[J]. Cancer, 1995,75 (8) :2147 - 52.
